Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants
Outlook Therapeutics (OTLK), a biopharmaceutical company specializing in bevacizumab treatments for retina diseases, has announced a proposed public offering of common stock and warrants. The offering will be managed by BTIG, LLC as the sole book-running manager. The company plans to use the proceeds for working capital and general corporate purposes.
The securities will be offered under a previously effective shelf registration statement (Form S-3, No. 333-278340). The final size, terms, and completion of the offering are subject to market conditions and cannot be guaranteed. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC.
Outlook Therapeutics (OTLK), un'azienda biofarmaceutica specializzata in trattamenti con bevacizumab per le malattie della retina, ha annunciato una proposta di offerta pubblica di azioni ordinarie e warrant. L'offerta sarà gestita da BTIG, LLC come unico gestore principale. La società intende utilizzare i proventi per il capitale circolante e scopi aziendali generali.
I titoli saranno offerti ai sensi di una dichiarazione di registrazione a scaffale precedentemente efficace (Modulo S-3, n. 333-278340). La dimensione finale, i termini e il completamento dell'offerta dipenderanno dalle condizioni di mercato e non possono essere garantiti. Sarà presentato alla SEC un supplemento al prospetto preliminare insieme al prospetto correlato.
Outlook Therapeutics (OTLK), una compañía biofarmacéutica especializada en tratamientos con bevacizumab para enfermedades de la retina, ha anunciado una propuesta de oferta pública de acciones ordinarias y warrants. La oferta será gestionada por BTIG, LLC como único administrador principal. La empresa planea usar los ingresos para capital de trabajo y propósitos corporativos generales.
Los valores se ofrecerán bajo una declaración de registro en estantería previamente efectiva (Formulario S-3, No. 333-278340). El tamaño final, los términos y la finalización de la oferta están sujetos a las condiciones del mercado y no pueden garantizarse. Se presentará un suplemento preliminar al prospecto junto con el prospecto correspondiente ante la SEC.
Outlook Therapeutics (OTLK)는 망막 질환 치료용 베바시주맙에 특화된 생명공학 제약 회사로, 보통주 및 워런트 공모를 제안했다고 발표했습니다. 이 공모는 단독 주관사인 BTIG, LLC가 관리할 예정입니다. 회사는 조달 자금을 운전자본 및 일반 기업 목적에 사용할 계획입니다.
증권은 이전에 효력이 있었던 선반 등록 명세서(Form S-3, No. 333-278340)에 따라 제공됩니다. 최종 규모, 조건 및 공모 완료는 시장 상황에 따라 달라지며 보장할 수 없습니다. 예비 투자설명서 보충서와 함께 관련 투자설명서가 SEC에 제출될 예정입니다.
Outlook Therapeutics (OTLK), une société biopharmaceutique spécialisée dans les traitements au bévacizumab pour les maladies de la rétine, a annoncé une offre publique proposée d’actions ordinaires et de bons de souscription. L’offre sera gérée par BTIG, LLC en tant que gestionnaire principal unique. La société prévoit d’utiliser les fonds levés pour le fonds de roulement et des fins générales d’entreprise.
Les titres seront proposés dans le cadre d’une déclaration d’enregistrement en étagère précédemment effective (Formulaire S-3, n° 333-278340). La taille finale, les modalités et la réalisation de l’offre dépendent des conditions du marché et ne peuvent être garanties. Un supplément au prospectus préliminaire ainsi que le prospectus accompagnant seront déposés auprès de la SEC.
Outlook Therapeutics (OTLK), ein biopharmazeutisches Unternehmen, das sich auf Bevacizumab-Behandlungen für Netzhauterkrankungen spezialisiert hat, hat ein geplantes öffentliches Angebot von Stammaktien und Warrants angekündigt. Das Angebot wird von BTIG, LLC als alleinigem Book-Running-Manager geleitet. Das Unternehmen plant, die Erlöse für das Betriebskapital und allgemeine Unternehmenszwecke zu verwenden.
Die Wertpapiere werden im Rahmen einer zuvor wirksamen Shelf-Registrierungserklärung (Formular S-3, Nr. 333-278340) angeboten. Die endgültige Größe, die Bedingungen und der Abschluss des Angebots hängen von den Marktbedingungen ab und können nicht garantiert werden. Ein vorläufiger Prospektergänzungsbericht sowie der dazugehörige Prospekt werden bei der SEC eingereicht.
- Potential to strengthen working capital position
- Additional funds for general corporate purposes
- Potential dilution for existing shareholders
- Stock price pressure from warrant offerings
- Uncertainty regarding offering terms and completion
Insights
Outlook Therapeutics is raising capital through stock and warrant offering, likely diluting existing shareholders to fund operations.
Outlook Therapeutics has announced a public offering of common stock and accompanying warrants, signaling an immediate need for capital. This move comes as the company continues developing bevacizumab treatments for retinal diseases. The offering will be managed by BTIG as the sole book-runner, suggesting a structured approach to the capital raise.
The announcement provides minimal details regarding the size, pricing, or exact terms of the offering, indicating the deal structure is still being finalized. While the company states the proceeds will be used for "working capital and general corporate purposes," this vague description typically translates to funding ongoing operations and potentially research activities.
This financing appears to be an opportunistic capital raise using their effective shelf registration from April 5, 2024. For existing shareholders, this offering will almost certainly result in equity dilution, as new shares entering the market will reduce current investors' ownership percentages and potentially pressure the stock price in the near term.
The inclusion of warrants alongside common stock suggests the company is offering additional incentives to attract investors, which is common for smaller biopharmaceutical companies seeking to enhance the appeal of their offerings. The company's need for additional funding indicates they likely don't have sufficient cash reserves to achieve their next significant milestone without this capital injection.
This type of financing is standard practice for pre-commercial biopharmaceutical companies, but does highlight Outlook's ongoing dependence on capital markets to sustain operations while pursuing FDA approval or commercial success for their bevacizumab products.
ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Outlook Therapeutics intends to use the net proceeds from the offering for working capital and other general corporate purposes.
BTIG, LLC is acting as sole book-running manager for the offering.
The securities described above are being offered by Outlook Therapeutics pursuant to a shelf registration statement on Form S-3 (No. 333-278340) that was declared effective by the Securities and Exchange Commission (SEC) on April 5, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, by contacting: BTIG, LLC, 65 East 55th Street, New York, New York 10022, by telephone at (212) 593-7555 or by email at ProspectusDelivery@btig.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and Medicines and Healthcare products Regulatory Agency Marketing Authorization for the treatment of wet age-related macular degeneration (wet AMD). Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the European Union and the United Kingdom as a treatment for wet AMD, expected in the second quarter of calendar 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, and a Biologics License Application has been resubmitted to the U.S. Food and Drug Administration. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “expect,” “may,” “plan,” “potential,” “will,” or “would” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, statements regarding Outlook Therapeutics’ intention to conduct an offering and sale of securities, the size of the offering, the completion of the proposed offering, the expected use of proceeds from the proposed offering, expectations concerning decisions of regulatory bodies and the timing thereof, plans for commercial launch of LYTENAVA™ in the EU and the UK and the timing thereof and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include fluctuations in Outlook Therapeutics’ stock price, changes in market conditions and satisfaction of customary closing conditions related to the offering, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, and the sufficiency of Outlook Therapeutics’ resources, as well as those risks detailed in Outlook Therapeutics’ filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended September 30, 2024, filed with the SEC on December 27, 2024, as supplemented by the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025, and subsequent filings with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, tariffs and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
Source: Outlook Therapeutics, Inc.
FAQ
What is the purpose of OTLK's public offering of common stock and warrants?
Who is managing Outlook Therapeutics' (OTLK) public offering?
What is Outlook Therapeutics' (OTLK) main business focus?
Under which SEC registration is OTLK conducting this offering?
How will this offering affect existing OTLK shareholders?
